Sunil R. Hingorani

Appointments and Affiliations


Fred Hutchinson Cancer Research Center
Clinical Research Division
Public Health Sciences Division

University of Washington
School of Medicine
Department of Medicine

Professional Headshot of Sunil R. Hingorani

Mailing Address

1100 Fairview Avenue North
Mailstop: M5-C800
Seattle, Washington 98109
United States


Phone: (206) 667-6921
Fax: (206) 667-7576


M.D., Yale University, Medicine, 1994.
Ph.D., Yale University, Cellular & Molecular Physiology, 1994.
B.S., Yale University, Molecular Biophysics & Biochemistry, 1985.

Research Interests

The Hingorani laboratory investigates the molecular and cellular mechanisms that drive the pathogenesis of pancreatic ductal adenocarcinoma (PDA) or, more commonly, pancreas cancer.  The inability to detect the disease early together with multiple mechanisms of chemical and radiotherapeutic resistance contribute to the extreme lethality of PDA.  Our goal is to identify the most compelling strategies to translate to the clinic in order to cure this disease. 

We have undertaken a systematic effort to deconstruct the cell autonomous and non-cell autonomous factors that cooperate to produce this unusually aggressive and lethal disease.  To this end, we have helped to develop a number of genetically engineered, highly faithful animal models of preinvasive, invasive and metastatic PDA through the targeted endogenous expression of mutations in a key oncogene and select tumor suppressor genes.  These models faithfully recapitulate the clinical syndrome, pathophysiology and molecular features of the distinct histopathologic routes to human pancreas cancer, including manifesting the unique stromal and immune responses that constitute the characteristic “desmoplastic reaction.”  These models also serve as the primary platforms for our Murine Clinical Trials Program (“Mouse Hospital”) designed to accelerate the translation of early detection, diagnostic and treatment strategies to the clinic.  As recent examples, our insights into combined stromal and epithelial cell targeting form the basis for international, randomized clinical trials currently underway.  We have also characterized unusual physicomechanical properties of this cancer, with respect to an abundant interstitial gel-fluid phase, as well as identified a concerted transcriptional program that drives metastasis.


American Association for Cancer Research
American Society of Clinical Oncology

Honors and Awards

2007, Scientific Director, Michael Rolfe Pancreatic Cancer Foundation
2005, Laurence A. Mack Career Development Award in Pancreatic Cancer Research, American Association for Cancer Research/PanCAN Foundation
2004, Scholar in Training Award, American Association for Cancer Research
1988-1993, Howard Hughes Pre-Doctoral Fellowship Award, Howard Huges Foundation
1985, Summa cum laude, Yale University
1983, Phi Beta Kappa Honor Society, Phi Beta Kappa Honor Society

Previous Positions

2006-2011, Assistant Professor, Department of Medicine, University of Washington School of Medicine, Seattle, WA
2005-2010, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research, Public Health Sciences
2003-2005, Attending Physician, Philadelphia Veterans' Administration Medical Center, Hematology/Oncology
2002-2005, Instructor, University of Pennsylvania, Abramson Cancer Center and Abramson Family Cancer Research Institute, Medicine and Cancer Biology
1999-2000, Post-Doctoral Research Fellow, Massachusetts Institute of Technology
1997-2000, Clinical Fellow, Brigham and Women's Hospital, Internal Medicine
1997-2000, Clinical Fellow, Dana-Farber/Partners Cancer Care Program, Hematology and Oncology
1994-1997, Intern, Brigham and Women's Hospital, Department of Internal Medicine


Recent Publications

Stromnes IM, Greenberg PD, Hingorani SR.  2014.  Molecular Pathways: Myeloid Complicity in Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(20):5157-70. Abstract
Hingorani SR, Potter JD.  2012.  Pancreas cancer meets the thunder god.. Science translational medicine. 4(156):156ps21. Abstract